

Press release

26 May, 2023

Curasight to present at HC Andersen Capital and Økonomisk Ugebrev

Copenhagen, Denmark, 26 May 2023 - Curasight A/S ("Curasight" or the "Company" - TICKER: CURAS) hereby announces that CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær will present the company's Interim Report Q1 2023 at HC Andersen Capital and at Økonomisk Ugebrev, 31 May 2023.

The presentation will include an update on the business progress made by the company during the first part of 2023 and look ahead at the coming news flow expected in rest of H1 2023. Management will give an overall update on the company's pipeline based on the proprietary uPAR theranostics platform and focused on diagnosing and treating brain and prostate cancer besides the newly signed global partnership agreement with Curium.

The HC Andersen Capital presentation will be webcasted live 10:30 - 11:00 (CET), Wednesday 31 May 2023.

An archive of the presentation can be found on the HC Andersen Capital website as well as Curasight's website, after the presentation is completed.

For more information – please [click here](#)

The Økonomisk Ugebrev Life Science Investor Conference will be conducted Wednesday, 31 May 2023 13:30 - 17:30 CET at Symbion, Copenhagen.

For more information – please [click here](#)

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO
Phone: +45 22 83 01 60
E-mail: uk@curasight.com
www.curasight.com

Curasight is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor ("uPAR"). The technology is expected to improve diagnosis and risk stratification in multiple cancer types.